Comparing two targeted therapies for early HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This study compares two treatments for early-stage HER2-positive breast cancer that has not spread to lymph nodes. One treatment is a newer drug called T-DXd, and the other is a combination of two older drugs (THP). The goal is to see which is more effective and safe for patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and at least 18 years old.
- You have been diagnosed with HER2-positive breast cancer (a test shows high levels of the HER2 protein) that has not been treated yet.
- The tumor is larger than 2 cm but not larger than 5 cm, and it has not spread to lymph nodes or other parts of the body (stage cT2, cN0, M0).
- Your heart function is normal (at least 50% ejection fraction) and your overall health is good (ECOG performance status 0 or 1).
- Your blood counts and organ function are within normal limits.
- You are not pregnant and are willing to use effective birth control during the study and for 7 months after treatment (if you could become pregnant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different treatments for women with HER2-positive early breast cancer who had a complete response to initial therapy but still have cancer DNA in their blood. It aims to see which treatment is better at preventing the cancer from coming back.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests if giving two HER2-targeted drugs together works as well when one is injected under the skin as when it is given through an IV. It aims to find a more convenient option for early-stage breast cancer patients.
This trial tests two targeted drugs, trastuzumab rezetecan and trastuzumab deruxtecan, to see which works better for HER2-positive breast cancer that has spread or cannot be removed by surgery. These drugs target the HER2 protein on cancer cells to slow or stop their growth.
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.